Altre lingue ZYUS Life Sciences Corporation

Azioni

ZYUS

CA9899601095

Mercato chiuso - Toronto S.E. Altri mercati azionari 20:52:16 10/05/2024			Variaz. 5gg	Var. 1 gen.
1,11 ^CAD	-5,13%		+11,00%	+23,33%

07/05	ZYUS Life Sciences Corporation riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
01/02	Zyus nomina il Dr. Hance Clarke nel Comitato di Consulenza Clinica	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

ZYUS Announces Completion of Its Annual Filings	08/05
INSERTING and REPLACING ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9	08/05
ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	07/05
ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate	23/04
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management	23/04
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets	05/03
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	20/02
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	20/02
ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke	02/02
ZYUS Life Sciences Appoints Dr. Hance Clarke to Clinical Advisory Committee	01/02
Zyus Appoints Dr. Hance Clarke as Clinical Advisory Committee	01/02
ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research	10/01
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Management	06/12
ZYUS Life Sciences Corp. Announces Phase 2 Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Care	05/12
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management	05/12
ZYUS Life Sciences Corporation Reports Q3 2023 Results	30/11
ZYUS Life Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30/11
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin Softgels	22/11
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels	21/11
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels	21/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue ZYUS Life Sciences Corporation

Azioni

ZYUS

CA9899601095

Altre lingue

Filtri